Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials. Pediatric ...

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, about the current research in treatments. Transcription: Hi, ...

The Student Visionaries of the Year campaign cultivates teen leadership while advancing Blood Cancer United's mission. The ...

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Mike and Sofia Segal, who immigrated to the U.S. from present-day Ukraine in 1978, lead foundation that supports overlooked and underfunded causes, including rare diseases RYE BROOK, N.Y., Oct. 25, ...

Saturday night was a special night for 16 local high schools, as it was the grand finale celebration for the Leukemia and Lymphoma Society's Student Visionaries of the Year program.Sixteen teams spent ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will ...

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for ...